N‐Salicyloyltryptamine, a new anticonvulsant drug, acts on voltage‐dependent Na+, Ca2+, and K+ ion channels

The aim of this work was to study the effects of N‐salicyloyltryptamine (STP), a novel anticonvulsant agent, on voltage‐gated ion channels in GH3 cells. In this study, we show that STP at 17 μM inhibited up to 59.2±10.4% of the Ito and 73.1±8.56% of the IKD K+ currents in GH3 cells. Moreover, the in...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of pharmacology Vol. 140; no. 7; pp. 1331 - 1339
Main Authors Araújo, Demétrius Antonio Machado, Mafra, Roberta Amaral, Rodrigues, Andréia Laura Prates, Miguel‐Silva, Válter, Beirão, Paulo Sérgio Lacerda, De Almeida, Reinaldo Nóbrega, Quintans, Lucindo, Souza, Maria Fátima Vanderlei de, Cruz, Jader Santos
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.12.2003
Nature Publishing
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The aim of this work was to study the effects of N‐salicyloyltryptamine (STP), a novel anticonvulsant agent, on voltage‐gated ion channels in GH3 cells. In this study, we show that STP at 17 μM inhibited up to 59.2±10.4% of the Ito and 73.1±8.56% of the IKD K+ currents in GH3 cells. Moreover, the inhibitory activity of the drug STP on K+ currents was dose‐dependent (IC50=34.6±8.14 μM for Ito) and partially reversible after washing off. Repeated stimulation at 1 Hz (STP at 17 μM) led to the total disappearance of Ito current, and an enhancement of IKD. In the cell‐attached configuration, application of STP to the bath increased the open probability of large‐conductance Ca2+‐activated K+ channels. STP at 17 μM inhibited the L‐type Ca2+ current by 54.9±7.50% without any significant changes in the voltage dependence. STP at 170 μM inhibited the TTX‐sensitive Na+ current by 22.1±2.41%. At a lower concentration (17 μM), no effect on INa was observed. The pharmacological profile described here might contribute to the neuroprotective effect exerted by this compound in experimental ‘in vivo’ models. British Journal of Pharmacology (2003) 140, 1331–1339. doi:10.1038/sj.bjp.0705471
Bibliography:Department of Biochemistry and Immunology, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Av. Antonio Carlos, 6627, ICB‐UFMG‐Bloco K4‐Sala 167, Belo Horizonte CEP 31270‐901, Minas Gerais, Brazil
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Department of Biochemistry and Immunology, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Av. Antonio Carlos, 6627, ICB-UFMG-Bloco K4-Sala 167, Belo Horizonte CEP 31270-901, Minas Gerais, Brazil
ISSN:0007-1188
1476-5381
DOI:10.1038/sj.bjp.0705471